Verastem Oncology to Participate in Upcoming Investor Conferences

VSTM 10.31.2024

Full Press ReleaseSEC FilingsOur VSTM Tweets

About Gravity Analytica

Recent News

  • 01.23.2025 - Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
  • 01.15.2025 - Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
  • 01.14.2025 - Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Recent Filings

  • 01.23.2025 - 8-K Current report
  • 01.23.2025 - EX-99.1 EX-99.1
  • 01.21.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
PDF Version

BOSTON--(BUSINESS WIRE)--Oct. 31, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in the following upcoming investor conferences:

  • 2024 Truist Securities BioPharma Symposium onNovember 7, 2024
  • Guggenheim Healthcare Innovation Conference; fireside chat onWednesday, November 13, 2024at9:00 am EDT

A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors & Media section of the company’s website atwww.verastem.com. A replay of the webcast will be archived on the website for approximately 90 days following the presentation.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on RAS/MAPK-driven cancers, specifically novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition. For more information, please visitwww.verastem.comand follow us onLinkedIn.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241030694764/en/

For Investor and Media Inquiries:Julissa VianaVice President, Corporate Communications and Investor Relationsinvestors@verastem.comormedia@verastem.com

Source: Verastem Oncology

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com